Stockscreener 앱 받기
7.16
12.58%
0.80
시장 영업 전:
7.39
0.23
+3.21%
전일 마감가:
$6.36
열려 있는:
$6.43
하루 거래량:
59,022
Relative Volume:
0.51
시가총액:
$123.00M
수익:
$35.58M
순이익/손실:
$-17.89M
주가수익비율:
-10.49
EPS:
-0.6823
순현금흐름:
$-17.74M
1주 성능:
+9.65%
1개월 성능:
+30.90%
6개월 성능:
+107.54%
1년 성능:
+60.65%
1일 변동 폭
$6.38
$7.20
1주일 범위
$6.15
$7.20
52주 변동 폭
$3.28
$9.8212
Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile
명칭
Verrica Pharmaceuticals Inc
전화
484-453-3300
주소
10 NORTH HIGH STREET, WEST CHESTER, PA
Compare VRCA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VRCA
Verrica Pharmaceuticals Inc
|
7.16 | 123.00M | 35.58M | -17.89M | -17.74M | -0.6823 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-06 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-11-05 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-07-25 | 업그레이드 | Needham | Hold → Buy |
| 2023-03-22 | 개시 | Jefferies | Buy |
| 2023-02-13 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-05-25 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-05-14 | 개시 | RBC Capital Mkts | Outperform |
| 2020-12-24 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-06-30 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-24 | 개시 | Northland Capital | Outperform |
| 2020-03-24 | 개시 | Needham | Buy |
| 2019-02-21 | 개시 | H.C. Wainwright | Buy |
모두보기
Verrica Pharmaceuticals Inc 주식(VRCA)의 최신 뉴스
Positive Phase II data on Verrica and Lytix’ ruxotemitide in BCC - The Pharma Letter
Lytix Biopharma ASA: New Phase II Study Data from Lytix Biopharma's Partner Verrica Pharmaceuticals to be Presented at SID 2026 Highlight Potential Abscopal Effects of Ruxotemitide in Basal Cell Carcinoma - Finansavisen
In 9 patients, Verrica's skin cancer drug shrank untreated tumors 67% - Stock Titan
Verrica Pharmaceuticals Announces Upcoming Presentation of - GlobeNewswire
MSN Money - MSN
Verrica schedules May 12 webcast for Q1 results and update - Stock Titan
Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate ... - Caledonian Record
Verrica Pharmaceuticals to Report First Quarter 2026 - GlobeNewswire
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Short Interest Update - MarketBeat
Common Warts Pipeline 2026: Therapies Under Investigation, - openPR.com
Verrica Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
[ARS] Verrica Pharmaceuticals Inc. SEC Filing - Stock Titan
[DEF 14A] Verrica Pharmaceuticals Inc. Definitive Proxy Statement - Stock Titan
Verrica Pharmaceuticals (VRCA) Stock Sector Rotation (Momentum Building) 2026-04-18Pre Earnings - Newser
Analysts Have Conflicting Sentiments on These Healthcare Companies: Verrica Pharmaceuticals (VRCA) and Johnson & Johnson (JNJ) - The Globe and Mail
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Consensus Rating of "Reduce" by Brokerages - MarketBeat
VRCA: Strong commercial growth and advancing late-stage pipeline position the company for major catalysts - TradingView
Verrica to Present Phase 2 Data on Skin Cancer Therapy at SID Meeting - MyChesCo
Block Trades: Is Verrica Pharmaceuticals Inc benefiting from innovation trendsM&A Rumor & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Aug Rallies: Is Verrica Pharmaceuticals Inc stock good for income investors2026 Decliners & Low Risk Growth Stock Ideas - baoquankhu1.vn
Aug Big Picture: Will Verrica Pharmaceuticals Inc announce a stock split2026 Macro Impact & Consistent Profit Alerts - baoquankhu1.vn
What is the future of Verrica Pharmaceuticals (VRCA) Stock | Price at $5.40, Down 7.38%High Interest Stocks - Xã Thanh Hà
EPS Watch: Is Verrica Pharmaceuticals Inc stock a value trapWeekly Trend Report & Trade Opportunity Analysis - baoquankhu1.vn
Verrica Pharmaceuticals announces acceptance of late-breaking abstract highlighting potential abscopal effect of VP-315 for the treatment of basal cell carcinoma at the upcoming 2026 Society for Investigative Dermatology annual meeting - marketscreener.com
Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting - GlobeNewswire
Chart Watch: Will Verrica Pharmaceuticals Inc announce a stock splitMarket Volume Report & Real-Time Sentiment Analysis - baoquankhu1.vn
Verrica Pharmaceuticals (NASDAQ:VRCA) Cut to Strong Sell at Zacks Research - MarketBeat
Skin cancer drug data from Verrica wins late-breaker slot in Chicago - Stock Titan
Common Warts Treatment Market Outlook 2034: Insights on Clinical Trials, FDA/EMA/PMDA Approvals, NDA Progress, Therapeutics, Disease Prevalence, Mechanisms, Market Size, Key Companies | DelveInsight - Barchart.com
Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference - marketscreener.com
Will Verrica Pharmaceuticals (VRCA) Stock Miss Expectations | Price at $5.98, Up 9.32%Stock Picks - Xã Vĩnh Công
VRCA Stock Analysis: Verrica Pharmaceuticals Inc. $5.47 Price Trend Deep Dive - Cổng thông tin điện tử tỉnh Lào Cai
Published on: 2026-04-01 04:27:23 - baoquankhu1.vn
Market Trends: How does Verrica Pharmaceuticals Inc score in quality rankingsProfit Target & Safe Swing Trade Setups - baoquankhu1.vn
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Sees Large Growth in Short Interest - MarketBeat
Published on: 2026-03-31 18:08:06 - baoquankhu1.vn
Common Warts Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Verrica Pharma, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics, KinoPharma - Barchart.com
Nasdaq Moves: How does Verrica Pharmaceuticals Inc perform in inflationary periodsDollar Strength & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Verrica Pharmaceuticals to Present at Jefferies Global Healthcare Conference - MSN
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Verrica Pharmaceuticals reports 2025 results and YCANTH sales growth - MSN
Dip Buying: Is Verrica Pharmaceuticals Inc a turnaround story2026 EndofYear Setup & Short-Term High Return Strategies - baoquankhu1.vn
Verrica Pharmaceuticals appoints Chris Chapman as chief commercial officer - MSN
VRCA Investors Have the Opportunity to Join Investigation of Verrica Pharmaceuticals Inc. with the Schall Law Firm - weeklyvoice.com
VRCA Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA - weeklyvoice.com
Verrica Encounters Legal Trigger—Could This Be an Undervalued Opportunity for a Short Squeeze? - Bitget
Verrica Pharmaceuticals Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA - The Joplin Globe
FinancialContentVerrica Pharmaceuticals Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA - FinancialContent
Verrica Pharmaceuticals upgraded to buy from hold at Brookline - MSN
Verrica Pharmaceuticals schedules conference call to discuss 2025 results - MSN
Verrica Pharmaceuticals Reports 2025 Results and YCANTH Sales Growth - MyChesCo
Verrica Pharmaceuticals Inc (VRCA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):